Design, Synthesis, and Tripeptidyl Peptidase II Inhibitory Activity of a Novel Series of (S)-2,3-Dihydro-2-(4-alkyl-1H-imidazol-2-yl)-1H-indoles
摘要:
Butabindide, 1, was previously reported as a potent inhibitor (IC50 = 7 nM) of the serine protease enzyme tripeptidyl peptidase II (TPPII), an endogenous protease that degrades cholecystokinin-8 (CCK-8). We found that 1 has some inherent chemical instability, yielding diketopiperazine 2 fairly readily under mimicked physiological conditions. We therefore prepared imidazoles 3, which are void of 1's inherent instability, and have found that our novel analogues maintained comparable TPPII inhibitory activity (e.g.,for 3c, IC50 = 4 nM) as 1.
Design, Synthesis, and Tripeptidyl Peptidase II Inhibitory Activity of a Novel Series of (S)-2,3-Dihydro-2-(4-alkyl-1H-imidazol-2-yl)-1H-indoles
摘要:
Butabindide, 1, was previously reported as a potent inhibitor (IC50 = 7 nM) of the serine protease enzyme tripeptidyl peptidase II (TPPII), an endogenous protease that degrades cholecystokinin-8 (CCK-8). We found that 1 has some inherent chemical instability, yielding diketopiperazine 2 fairly readily under mimicked physiological conditions. We therefore prepared imidazoles 3, which are void of 1's inherent instability, and have found that our novel analogues maintained comparable TPPII inhibitory activity (e.g.,for 3c, IC50 = 4 nM) as 1.
The present invention is concerned with novel compounds of formula (I) which are inhibitors of a membrane tripeptidyl peptidase responsible for the inactivation of endogenous neuropeptides such as cholecystokinis (CCKs). The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.
1
wherein n is an integer 0 or 1; X represents O; S; or '(CR
4
R
5
)
m
— wherein m is an integer 1 or 2; R
4
and R
5
are each independently from each other hydrogen or C
1-4
alkyl; R
1
is C
1-6
alkylcarbonyl optionally substituted with hydroxy; C
1-6
alkyloxycarbonyl; aminoC
1-6
alkylcarbonyl wherein the C
1-6
alkyl group is optionally substituted with C
3-6
cycloalkyl; mono- and di(C
1-4
alkyl)aminoC
1-6
alkylcarbonyl; aminocarbonyl substituted with aryl; C
1-6
alkylcarbonyloxyC
1-6
alkylcarbonyl; C
1-6
alkyloxycarbonylaminoC
1-6
alkylcarbonyl wherein the amino group is optionally substituted with C
1-4
alkyl; an amino acid; C
1-6
alkyl substituted with amino; or arylcarbonyl; R
2
is an optionally substituted 5-membered heterocycle, or R
2
is optionally substituted benzimnidazole; R
3
is a bivalent radical —CH
2
CH
2
— optionally substituted with halo or phenylmethyl; or R
3
is a bivalent radical of formula
2
The present invention is concerned with novel compounds of formula (I) which are inhibitors of a membrane tripeptidyl peptidase responsible for the inactivation of endogenous neuropeptides such as cholecystokinis (CCKs). The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.
wherein n is an integer 0 or 1; X represents O; S; or —(CR
4
R
5
)
m
— wherein m is an integer 1 or 2; R
4
and R
5
are each independently from each other hydrogen or C
1-4
alkyl; R
1
is C
1-6
alkylcarbonyl optionally substituted with hydroxy; C
1-6
alkyloxycarbonyl; aminoC
1-6
alkylcarbonyl wherein the C
1-6
alkyl group is optionally substituted with C
3-6
cycloalkyl; mono- and di(C
1-4
alkyl)aminoC
1-6
alkylcarbonyl; aminocarbonyl substituted with aryl; C
1-6
alkylcarbonyloxyC
1-6
alkylcarbonyl; C
1-6
alkyloxycarbonylaminoC
1-6
alkylcarbonyl wherein the amino group is optionally substituted with C
1-4
alkyl; an amino acid; C
1-6
alkyl substituted with amino; or arylcarbonyl; R
2
is an optionally substituted 5-membered heterocycle, or R
2
is optionally substituted benzimidazole; R
3
is a bivalent radical —CH
2
CH
2
— optionally substituted with halo or phenylmethyl; or R
3
is a bivalent radical of formula